NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

PMN

ProMIS Neurosciences Inc

Dollar change -0.0262
Percentage change -4.10	%

Apr 04 • 04:00PM ET

0.6139

-0.0262-4.10%

Healthcare • Biotechnology • Canada • NASD

Peers: LLY BIIB REGN VRTX SAVA IONS ACAD AVXL NBIX PRTA

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.02	Insider Own	29.91%	Shs Outstand	32.69M	Perf Week	-12.30%
Market Cap	20.07M	Forward P/E	-	EPS next Y	-0.26	Insider Trans	0.15%	Shs Float	22.91M	Perf Month	-15.68%
Income	2.78M	PEG	-	EPS next Q	-0.15	Inst Own	24.88%	Short Float	0.88%	Perf Quarter	-36.05%
Sales	0.00M	P/S	-	EPS this Y	-649.27%	Inst Trans	-12.32%	Short Ratio	4.72	Perf Half Y	-50.09%
Book/sh	0.50	P/B	1.22	EPS next Y	56.97%	ROA	17.08%	Short Interest	0.20M	Perf Year	-72.81%
Cash/sh	0.41	P/C	1.51	EPS next 5Y	-	ROE	27.46%	52W Range	0.62 - 2.61	Perf YTD	-35.23%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	16.85%	52W High	-76.48%	Beta	0.03
Dividend TTM	-	Quick Ratio	8.52	Sales past 5Y	-10.59%	Gross Margin	-	52W Low	-1.12%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	8.52	EPS Y/Y TTM	98.61%	Oper. Margin	-	RSI (14)	35.81	Volatility	10.59% 8.98%
Employees	7	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	7.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	96.15%	Payout	0.00%	Rel Volume	1.31	Prev Close	0.64
Sales Surprise	-	EPS Surprise	185.71%	Sales Q/Q	-	Earnings	Mar 31 BMO	Avg Volume	42.46K	Price	0.61
SMA20	-13.45%	SMA50	-23.12%	SMA200	-45.50%	Trades		Volume	55,780	Change	-4.10%

Mar-31-25 07:00AM	ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights (GlobeNewswire)
Mar-24-25 07:00AM	ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference (GlobeNewswire)
Mar-13-25 07:00AM	ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting (GlobeNewswire)
Mar-11-25 07:30AM	ProMIS Neurosciences to Participate in the 37th Annual Roth Conference (GlobeNewswire)
Feb-25-25 07:00AM	ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease (GlobeNewswire) -6.19%
07:30AM	Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.Finviz Elite
Jan-29-25 07:30AM	ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Jan-13-25 10:30AM	ProMIS Neurosciences Issues Letter to Shareholders (GlobeNewswire)
Jan-10-25 07:00AM	ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer's Disease (GlobeNewswire)
Nov-26-24 07:00AM	ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference (GlobeNewswire)
Nov-14-24 09:15AM	ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
Nov-12-24 07:00AM	ProMIS Neurosciences to Participate in Guggenheim's Inaugural Healthcare Innovation Conference (GlobeNewswire)
Oct-30-24 08:00AM	ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference (GlobeNewswire) +5.83%
Oct-13-24 02:58PM	ProMIS Neurosciences, Inc. (PMN): Analysts Are Bullish On This Undervalued Canadian Stock Now (Insider Monkey)
Sep-12-24 07:00AM	ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences (GlobeNewswire)
Sep-05-24 07:00AM	ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
07:30AM	Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.Finviz Elite
Aug-12-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Aug-08-24 07:00AM	ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire) -11.51%
Aug-06-24 07:00AM	ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology (GlobeNewswire) +18.33%
Aug-01-24 07:00AM	ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024 (GlobeNewswire)
Jul-30-24 08:30AM	ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference (GlobeNewswire) -17.43%
Jul-26-24 08:35AM	ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial (GlobeNewswire) -20.70%
08:30AM	ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing (GlobeNewswire)
May-15-24 09:54AM	PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q1 2024 (InvestorPlace) -7.22%
May-14-24 04:01PM	ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
Apr-30-24 07:00AM	ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies (GlobeNewswire)
Apr-09-24 07:00AM	ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS (GlobeNewswire)
Apr-04-24 07:00AM	ProMIS Neurosciences to Present in Upcoming Investor Conferences in April (GlobeNewswire)
Apr-01-24 10:53PM	PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q4 2023 (InvestorPlace) +7.33% +10.15%
04:15PM	ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights (GlobeNewswire)
Mar-11-24 07:00AM	ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio (GlobeNewswire)
07:00AM	Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.Finviz Elite
Feb-22-24 07:00AM	ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference (GlobeNewswire) -10.14%
Jan-22-24 07:00AM	ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine (GlobeNewswire) +7.24%
Jan-08-24 07:00AM	ProMIS Neurosciences Issues Letter to Shareholders (GlobeNewswire) +5.45%
Jan-03-24 07:00AM	ProMIS Neurosciences, Inc. Announces Leadership Transition (GlobeNewswire) -7.82%
Dec-20-23 07:00AM	ProMIS Neurosciences Announces Publication on Novel Target for ALS (GlobeNewswire)
Nov-20-23 07:00AM	ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer's Disease (GlobeNewswire) +6.67%
Nov-14-23 04:30PM	ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire) -12.22% +9.36%
Sep-08-23 07:00AM	ProMIS Neurosciences Closes $20.4 Million Private Placement Financing (GlobeNewswire)
Sep-06-23 12:18PM	ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-21-23 04:12PM	ProMIS Neurosciences Announces $20.4 Million Private Placement Financing (GlobeNewswire) -9.14% +20.75%
Aug-14-23 05:33PM	ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire) -8.33%
Jul-17-23 07:00AM	ProMIS Showcases Preclinical Data at the Alzheimers Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimers Pipeline (GlobeNewswire) +120.28%
Jul-14-23 07:45AM	ProMIS Announces Completion of Continuance (GlobeNewswire)
Jul-10-23 07:55AM	ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange (GlobeNewswire) -8.11%
Jun-30-23 08:00AM	ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved (GlobeNewswire)
Jun-29-23 08:00AM	CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time (GlobeNewswire)
May-15-23 05:00PM	ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire) -8.16%
May-08-23 09:00AM	ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimers Disease (GlobeNewswire)
Apr-25-23 05:00PM	Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimers Disease (GlobeNewswire)
Apr-24-23 07:30AM	ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimers Disease and ALS at American Academy of Neurology Annual Meeting (GlobeNewswire) +8.31%
Apr-10-23 07:30AM	ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310 (GlobeNewswire)
Mar-29-23 08:30AM	Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023 (GlobeNewswire)

ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. It focuses on the progression of Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. The company was founded by Neil Cashman and Vigen Nazarian on January 23, 2004 and is headquartered in Toronto, Canada.

Institutional Ownership

GREAT POINT PARTNERS LLC	8.09%
ARMISTICE CAPITAL, LLC	7.68%
SPHERA FUNDS MANAGEMENT LTD.	5.90%
Ally Bridge Group	4.87%
Altium Capital Management LLC	1.78%
Allostery Investments LP	0.60%
HEIGHTS CAPITAL MANAGEMENT, INC	0.49%
BANK OF MONTREAL /CAN/	0.09%
Hara Capital LLC	0.09%
IEQ CAPITAL, LLC	0.08%

Insider Trading Volume

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cashman Neil	Chief Scientific Officer	Feb 10 '25	Buy	0.97	15,000	14,595	16,617	Feb 12 05:21 PM
Shafmaster Madge K.	Director	Sep 24 '24	Buy	1.30	70,000	91,028	208,333	Sep 24 06:56 PM
Shafmaster Madge K.	Director	Sep 23 '24	Buy	1.28	70,000	89,656	138,333	Sep 24 06:56 PM
Shafmaster Madge K.	Director	Sep 20 '24	Buy	1.25	60,000	75,066	68,333	Sep 24 06:56 PM
GORDON MICHAEL S	10% Owner	Sep 16 '24	Buy	1.22	76,931	94,071	76,931	Sep 18 04:15 PM
GORDON MICHAEL S	10% Owner	Sep 17 '24	Buy	1.40	16,292	22,809	93,223	Sep 18 04:15 PM
Kirwin Patrick D.	Director	Aug 14 '24	Buy	1.25	10,000	12,492	62,983	Aug 16 07:38 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PMN

ProMIS Neurosciences Inc

Institutional Ownership

Upgrade your FINVIZ experience